This clinical trial evaluating the benefit of continued CDK4/6 therapy after progression on a prior CDK4/6 inhibitor is to our knowledge unique in having carried out in-depth multi-omic tumor analysis in baseline metastatic tissue and blood samples taken after development of CDK4/6i resistance. The gene discussed is CDK4; the disease is neoplasm.